AQUA07 vs Ensartinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline

AQUA07

Developed by Chugai Pharma

Phase 1 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2030 · NCT07617337 (registry estimate)

No aligned efficacy figure on record for this race.

Ensartinib · Ensacove

Marketed by Xcovery Holdings and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02767804 · Phase 3 · active, not recruiting

This was a randomized, phase 3, active-controlled trial with 290 patients comparing ensartinib to crizotinib, using progression-free survival (a hard clinical endpoint) as the primary measure, and the trial met its primary endpoint with a large, statistically significant improvement favoring ensartinib. However, the study was open-label (no blinding of patients or investigators), which limits confidence in outcome assessments despite the use of independent radiology review, so the evidence is graded as solid but not the highest tier.

Next expected readout: February 2027 · NCT05241028 (registry estimate)

Reported efficacy

Progression-free survival (PFS) (36 months): eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001. (met)

Result source: NCT02767804

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAQUA07Ensartinib
PFS, median—Not reported—Trial running · NCT06955325
OS, median—Not reported—Trial running · NCT06955325
ORR—Not reported—Trial running · NCT06955325
Duration of response, median—Not reported—Trial running · NCT06955325

PFS, median

AQUA07
—Not reported
Ensartinib
—Trial running · NCT06955325

OS, median

AQUA07
—Not reported
Ensartinib
—Trial running · NCT06955325

ORR

AQUA07
—Not reported
Ensartinib
—Trial running · NCT06955325

Duration of response, median

AQUA07
—Not reported
Ensartinib
—Trial running · NCT06955325
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AQUA07: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. AQUA07: 0 of 4 rows · Ensartinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEnsartinib
Dropout rate
0%225 mga
NCT01625234 · Phase 1/2
show 7 more results
0%225 mg
NCT01625234 · Phase 1/2
0%250 mg
NCT01625234 · Phase 1/2
0%200 mg
NCT01625234 · Phase 1/2
0%100 mg
NCT01625234 · Phase 1/2
0%50 mg
NCT01625234 · Phase 1/2
0%25 mg
NCT01625234 · Phase 1/2
n/a: no completion milestone200 mg
NCT02898116 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
—225 mga
NCT01625234 · Phase 1/2
show 7 more results
—225 mg
NCT01625234 · Phase 1/2
—250 mg
NCT01625234 · Phase 1/2
—200 mg
NCT01625234 · Phase 1/2
—100 mg
NCT01625234 · Phase 1/2
—50 mg
NCT01625234 · Phase 1/2
—25 mg
NCT01625234 · Phase 1/2
50%200 mg
NCT02898116 · Phase 1/2 · registry result, not featured evidence
Serious AEs
50%225 mga
NCT01625234 · Phase 1/2
show 7 more results
43.6%225 mg
NCT01625234 · Phase 1/2
50%250 mg
NCT01625234 · Phase 1/2
54.5%200 mg
NCT01625234 · Phase 1/2
40%100 mg
NCT01625234 · Phase 1/2
33.3%50 mg
NCT01625234 · Phase 1/2
25%25 mg
NCT01625234 · Phase 1/2
50%200 mg
NCT02898116 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
225 mga
gastrointestinal disorders 25%
nausea 25%
vomiting 25%
NCT01625234 · Phase 1/2
show 7 more results
225 mg
gastrointestinal disorders 60.6%
nausea 38.3%
vomiting 25.5%
NCT01625234 · Phase 1/2
250 mg
gastrointestinal disorders 50%
vomiting 50%
nausea 30%
NCT01625234 · Phase 1/2
200 mg
gastrointestinal disorders 54.5%
nausea 45.5%
vomiting 36.4%
NCT01625234 · Phase 1/2
100 mg
gastrointestinal disorders 40%
anaemia 20%
blood and lymphatic 20%
NCT01625234 · Phase 1/2
50 mg
gastrointestinal disorders 33.3%
nausea 33.3%
vomiting 33.3%
NCT01625234 · Phase 1/2
25 mg
anaemia 25%
blood and lymphatic 25%
blood creatinine increased 25%
NCT01625234 · Phase 1/2
200 mg
hypoalbuminaemia 100%
anaemia 50%
arthralgia 50%
NCT02898116 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ensartinib

ORR 42% (n=81) @ 78wk225 mg
event count · % of participants
No placebo or comparator arm
NCT01625234 · Phase 1/2 · converted to % from 34 participants as posted
Stable Disease 0% (n=2)200 mg
event count · % of participants
No placebo or comparator arm
SD
NCT02898116 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted
Progressive Disease 100% (n=2)200 mg
event count · % of participants
No placebo or comparator arm
PD
NCT02898116 · Phase 1/2 · registry result, not featured evidence · converted to % from 2 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AQUA07's landscape · Ensartinib's landscape